ValuEngine lowered shares of TESARO, Inc. (NASDAQ:TSRO) from a hold rating to a sell rating in a research note published on Tuesday.
A number of other equities analysts have also issued reports on the company. Credit Suisse Group set a $198.00 target price on TESARO and gave the stock a buy rating in a research note on Wednesday, July 19th. Leerink Swann reduced their price objective on TESARO from $164.00 to $143.00 and set a market perform rating for the company in a research note on Tuesday, June 20th. Gabelli began coverage on TESARO in a research note on Friday, July 7th. They set a buy rating and a $175.00 price objective for the company. Cann reiterated a buy rating and set a $199.00 price objective on shares of TESARO in a research note on Friday, September 8th. Finally, BidaskClub lowered TESARO from a sell rating to a strong sell rating in a research note on Wednesday, July 19th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. TESARO currently has a consensus rating of Buy and an average price target of $170.74.
Shares of TESARO (TSRO) opened at 118.22 on Tuesday. The company’s 50-day moving average price is $122.34 and its 200-day moving average price is $134.50. TESARO has a 52-week low of $96.52 and a 52-week high of $192.94. The stock’s market cap is $6.41 billion.
TESARO (NASDAQ:TSRO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.52) by ($0.30). The firm had revenue of $29.50 million during the quarter, compared to analysts’ expectations of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The business’s revenue was down 17.6% on a year-over-year basis. During the same quarter last year, the business earned ($1.28) EPS. On average, equities research analysts forecast that TESARO will post ($8.63) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “TESARO, Inc. (TSRO) Downgraded by ValuEngine to Sell” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://stocknewstimes.com/2017/10/11/tesaro-inc-tsro-downgraded-by-valuengine-to-sell.html.
In related news, VP Edward C. English sold 10,862 shares of TESARO stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $134.92, for a total value of $1,465,501.04. Following the sale, the vice president now directly owns 6,258 shares in the company, valued at approximately $844,329.36. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Grant C. Bogle sold 14,167 shares of TESARO stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,692 shares of company stock worth $4,628,976. 34.60% of the stock is currently owned by insiders.
Hedge funds have recently bought and sold shares of the stock. Botty Investors LLC acquired a new stake in TESARO in the 2nd quarter worth about $140,000. Nordea Investment Management AB acquired a new stake in TESARO in the 2nd quarter worth about $167,000. Meeder Asset Management Inc. acquired a new stake in TESARO in the 1st quarter worth about $177,000. Oppenheimer Asset Management Inc. boosted its holdings in TESARO by 3,042.6% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after buying an additional 1,430 shares during the last quarter. Finally, BB&T Securities LLC acquired a new stake in TESARO in the 2nd quarter worth about $222,000.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.